Company intelligence / Profile preview
Vector-BiAlgam
Koltsovo, Novosibirsk Oblast, Russiabialgam.ru ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Vector-BiAlgam is the sole Russian producer of ALGAVAK®M (Hepatitis A vaccine), is an industrial manufacturer of the EpiVacCorona COVID-19 vaccine, and supplies multiple clinically validated probiotic and biotherapeutic products. Their Hepatitis A vaccine is GMP-certified and shown to be as effective as foreign analogues, without antibiotics or preservatives. Their dietary supplements and probiotics are clinically validated for digestive and metabolic health.
- Therapeutic areas
- ImmunologyInfectious DiseasesCardiovascularGastroenterology
- Modalities
- VaccineProbioticSmall moleculeFermentBiologic
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Vektor State Research Center of Virology and BiotechnologyGeropharm
Beyond the preview
Go deeper on Vector-BiAlgam.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vector-BiAlgam.